NasdaqGS:TNYABiotechs
Is Tenaya Therapeutics’ (TNYA) 2026 Gene Therapy Milestone Roadmap Reframing Its Long-Term Risk Profile?
In January 2026, Tenaya Therapeutics outlined past and upcoming 2026 milestones for its TN-201 and TN-401 gene therapy programs, including interim MyPEAK-1 data, additional RIDGE-1 updates, and plans to seek regulatory alignment on potential pivotal studies.
A key insight is that both programs target genetically defined cardiac conditions with U.S. FDA designations and planned data readouts that could clarify each therapy’s clinical risk profile and development path.
We will now examine how...